Status quo of chronic liver diseases, including hepatocellular Carcinoma, in Mongolia

Korean Journal of Internal Medicine

Volumn 27, Issue 2, 2012, Pages 121-127

  Jazag, Amarsanaa ^a,b   Puntsagdulam, Natsagnyam ^b   Chinburen, Jigjidsuren ^c  

^a Mongolian National Research Institute   (Mongolia)

^b Mongolian Association for the Study of Liver Diseases (MASLD)   (Mongolia)

^c National Cancer Center of Mongolia   (Mongolia)

Author keywords

Carcinoma; Hepatocellular; Liver cirrhosis; Mongolia

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY;

ALCOHOL CONSUMPTION; ANTIVIRAL THERAPY; CANCER MORTALITY; CANCER STAGING; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; MONGOLIA; MORBIDITY; REVIEW; SEROPREVALENCE; SURVIVAL RATE; TUMOR ABLATION;

CARCINOMA, HEPATOCELLULAR; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; LIVER NEOPLASMS; MONGOLIA; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; TIME FACTORS;

EID: 84862893939     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2012.27.2.121     Document Type: Review

References (13)

1. Ministry of Health. National Health Indicator 2009. Ulaanbaatar: Ministry of Health, 2009.
2. Nymadawa P. Hepatitis B vaccination: worldwide and in Mongolia. In: 10th National Conference on "Current Topics of Virology" 2004; Ulaanbaatar, Mongolia.
3. Baatarkhuu O, Kim DY, Ahn SH, et al. Prevalence and genotype distribution of hepatitis C virus among apparently healthy individuals in Mongolia: a population-based nationwide study. Liver Int 2008;28:1389-1395.
4. Cohen J. The scientific challenge of hepatitis C. Science 1999;285:26-30.
5. Stark K, Poggensee G, Hohne M, Bienzle U, Kiwelu I, Schreier E. Seroepidemiology of TT virus, GBC-C/HGV, and hepatitis viruses B, C, and E among women in a rural area of Tanzania. J Med Virol 2000;62:524-530.
6. Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000;355:887-891.
7. Tsatsralt-Od B, Takahashi M, Nishizawa T, Inoue J, Ulaankhuu D, Okamoto H. High prevalence of hepatitis B, C and delta virus infections among blood donors in Mongolia. Arch Virol 2005;150:2513-2528.
8. Tsatsralt-Od B, Takahashi M, Nishizawa T, Endo K, Inoue J, Okamoto H. High prevalence of dual or triple infection of hepatitis B, C, and delta viruses among patients with chronic liver disease in Mongolia. J Med Virol 2005;77:491-499.
9. Dondog B, Lise M, Dondov O, Baldandorj B, Franceschi S. Hepatitis B and C virus infections in hepatocellular carcinoma and cirrhosis in Mongolia. Eur J Cancer Prev 2011;20:33-39.
10. Kurbanov F, Tanaka Y, Elkady A, Oyunsuren T, Mizokami M. Tracing hepatitis C and Delta viruses to estimate their contribution in HCC rates in Mongolia. J Viral Hepat 2007;14:667-674.
11. Oyunsuren T, Kurbanov F, Tanaka Y, et al. High frequency of hepatocellular carcinoma in Mongolia: association with mono-, or co-infection with hepatitis C, B, and delta viruses. J Med Virol 2006;78:1688-1695.
12. Oyunsuren T, Sanduijav R, Davaadorj D, Nansalmaa D. Hepatocellular carcinoma and its early detection by AFP testing in Mongolia. Asian Pac J Cancer Prev 2006;7:460-462.
13. Jazag A, Puntsagdulam N. Demography and mortality of patients undergone liver resection due to HCC at National Cancer Center in Mongolia. In: APASL 2nd Hepatocellular carcinoma Conference; 2011 Dec 1-3; Jeju, Korea.